Acquisition Announced
Novartis acquisition of Avidity Biosciences
US$11bn enterprise value
Announced 26 Oct 2025 · NYSE: RNA · US$72.00 cash per share
Advisers
Avidity Biosciences
Target
- Target
- Avidity Biosciences
- Acquirer
- Novartis
- Target based in
- United States
- Buyer based in
- Switzerland
- Equity value
- US$12bn
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Drug Development
In the league tables
Similar deals
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
Sources
- 30 Jan 2026 Definitive merger proxy statement (DEFM14A), Avidity Biosciences, Inc. sec.gov
- 27 Feb 2026 Novartis — Novartis acquisition of Avidity Biosciences novartis.com



